Martinez S, Gonzalez M, Vernaza M E
Department of Internal Medicine, University of Cauca, Popayan, and the University Hospital of San Jose of Popayan, Columbia.
Clin Infect Dis. 1997 Feb;24(2):165-9. doi: 10.1093/clinids/24.2.165.
We conducted a randomized, controlled study in southern Colombia to determine if the addition of allopurinol to stibogluconate was superior to stibogluconate alone in the treatment of cutaneous leishmaniasis. Lesions that healed after a 3-month course of therapy and remained so during a 1-year period of follow-up were considered cured. The cure rate for patients treated with stibogluconate was 39%; the addition of allopurinol increased this rate to 71% (P = .005). For the treatment of cutaneous leishmaniasis, the combination of allopurinol and stibogluconate is significantly more effective than is stibogluconate alone. These results support those of other clinical studies in which allopurinol and stibogluconate were shown to be superior to stibogluconate alone. The aggregate data support the use of allopurinol as an inexpensive, orally administered agent that can be used as an adjunct to stibogluconate or, perhaps, other oral agents in the treatment of cutaneous leishmaniasis.
我们在哥伦比亚南部开展了一项随机对照研究，以确定在治疗皮肤利什曼病时，将别嘌呤醇添加到葡萄糖酸锑钠中是否比单独使用葡萄糖酸锑钠更具优势。经过3个月疗程治疗后愈合且在1年随访期内保持愈合的皮损被视为治愈。接受葡萄糖酸锑钠治疗的患者治愈率为39%；添加别嘌呤醇后治愈率提高到71%（P = 0.005）。对于皮肤利什曼病的治疗，别嘌呤醇与葡萄糖酸锑钠联合使用比单独使用葡萄糖酸锑钠显著更有效。这些结果支持了其他临床研究的结果，即在这些研究中别嘌呤醇和葡萄糖酸锑钠被证明优于单独使用葡萄糖酸锑钠。汇总数据支持将别嘌呤醇用作一种廉价的口服药物，可作为葡萄糖酸锑钠或或许其他口服药物治疗皮肤利什曼病的辅助药物。
